摘要
目的比较两种前列腺素依前列醇钠、前列地尔在体外抑制二磷酸腺苷(adenosine diphosphate,ADP)诱导的血小板聚集的强弱。方法SD大鼠腹腔静脉取血,制得血小板数400×10~9个/L的血小板混悬液。血小板混悬液中加入不同浓度的依前列醇钠和前列地尔(50、125、250、500、2500 ng/ml)在最佳ADP浓度和最佳孵育时间,分别测定5 min内最大聚集率,各浓度检测4次取平均值,从而得到依前列醇钠、前列地尔量效关系并进行对比。结果ADP最佳诱导浓度为20μM,最佳孵育时间为5 min,随着依前列醇钠、前列地尔浓度的增加,血小板聚集率依次降低。依前列醇钠5个浓度血小板抑制率依次为19.61%、48.13%、88.25%、93.71%和100.00%,前列地尔5个浓度血小板抑制率依次为5.20%、11.70%、23.16%、28.10%和65.09%。结论依前列醇钠、前列地尔均具有血小板聚集抑制作用,并呈浓度依赖性,且依前列醇钠的血小板抑制作用远远强于前列地尔。
Objective To investigate the inhibitory effects of two types of prostaglandins(epoprostenol sodium and prostaglandin E1)on adenosine diphosphate(ADP)-induced platelet aggregation in vitro.Methods Platelet suspension was incubated with epoprostenol sodium and prostaglandin E1 respectively at different concentrations(0,50,125,500 and 2500 ng/ml)before the maximal extent of platelet aggregation was determined at the best ADP concentration and the best incubation time.Results At 20μM ADP and after incubation of 5 min,the platelet aggregation of both types of prostaglandins induced by ADP was reduced accordingly with the increase of the concentrations of epoprostenol sodium and prostaglandin E1.The inhibitory rate of platelet aggregation induced by epoprostenol sodium was 19.61%,48.13%,88.25%,93.71%,and 100%respectively,compared with 5.20%,11.70%,23.16%,28.10%and 65.09%respectively for prostaglandin E1.Conclusions Epoprostenol sodium and prostaglandin E1 can inhibit ADP-induced platelet aggregation in a concentration-dependent manner in vitro,and the former is more effective.
作者
夏晴
李艺
李薇
胡惠静
陈云
阮竞雄
XIA Qing;LI Yi;LI Wei;HU Huijing;CHEN Yun;RUAN Jingxiong(Department of Pharmacy,Air Force No.986 Hospital,Xi’an 710054,China;Xi’an Libang Zhaoxin Biotechnology Limited Company,Xi’an 710077,China;Department of Clinical Laboratory,the First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China)
出处
《武警医学》
CAS
2020年第3期195-198,共4页
Medical Journal of the Chinese People's Armed Police Force
关键词
依前列醇钠
前列地尔
二磷酸腺苷
血小板聚集率
epoprostenol sodium
prostaglandin E1
adenosine diphosphate
platelet aggregation
